In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and ...

Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is ...

Pelvic Cancer Induced Hemorrhegic Cystitis MarketThe global pelvic cancer induced hemorrhagic cystitis market size is estimated to achieve an amazing valuation of USD 2.1 billion in 2023 and reach USD ...

The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...

The fight against Age Related Molecular Degeneration Market is seeing a promising boost. According to a recent analysis, the ...

SALES FORECAST: The Swiss pharma giant's third-quarter sales are forecast at 14.89 billion Swiss francs ($17.22 billion), according to a consensus of 11 analysts' estimates compiled by Visible Alpha.

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

"We are essentially moving from a situation of defeating the enemy in all the contact villages to a state of destruction." Information ...